Latest news with #ImmunoCure
Malay Mail
16 hours ago
- Business
- Malay Mail
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA. Immuno Cure , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—theto form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities:, said: "We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation."Ahead of BIO 2025, the delegation participated in the "2025 Biomedical Pitch Competition", co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as "Edison of Medicine"), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at
South China Morning Post
28-01-2025
- Health
- South China Morning Post
Hong Kong life and health tech entrepreneurs on shared quest to make the world healthier
04:17 Hong Kong entrepreneurs share global visions for healthcare during breathwork session Hong Kong entrepreneurs share global visions for healthcare during breathwork session On a winter afternoon, three life and health technology entrepreneurs and a breathwork specialist, all based in Hong Kong, have come together to share their visions of how to make the world a healthier place. They chose to do so during an outdoor breathing exercise session, where they explored how the practice could help them stay in top form and power ahead on their innovation journeys. 'I trained as a doctor, but the tools available to doctors are limited. There are a lot of new diseases coming, but medicines are limited,' says Xia Jin, one of the session's participants, who is co-founder and CEO of Immuno Cure. 'I felt that by getting into the academic field, I could help develop new medicines and treat more patients.' The company's mission is to bridge the gap between the scientific discovery and the making of a drug through biotech. It is making good headway with a therapeutic HIV vaccine and an antibody for cancer treatment, both of which are going through clinical trials. 'Both our vaccine and antibody are first in class,' Jin says. 'They have global patents. Once the product is patented globally, it represents the first creation of such a product.' Brian Lai, the session's instructor and founder of Primal Breathwork in Hong Kong, was inspired to start his company by his own past struggle with mental health. That experience led him to a meditation retreat where he discovered the power of breathwork.
